ConductScience.org, home

Paper36790010

Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know.

Young JS and 4 others. J Neurosurg, 2023. Cited by 48 papers, by iCite.

Cite this record

ConductScience Library. Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know. Papers, record 36790010. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36790010

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know.
PubMed
Journal
J Neurosurg
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
48
iCite
Relative citation ratio, by iCite
6.35
iCite
Revised in PubMed
2023-10-03
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Young JSJacob S
2Al-Adli NNadeem
3Scotford KKatie
4Cha SSoonmee
5Berger MSMitchel S

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
GlioblastomaMajor topic
Brain NeoplasmsMajor topic
Humans
Neurosurgeons
Disease Progression
Magnetic Resonance Imaging

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
T32 CA151022NCI NIH HHSUnited StatesT32CA151022PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References79

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120399573Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.Int J Radiat Oncol Biol Phys2011https://conductscience.org/library/papers/20399573PubMed
220732762Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.Int J Radiat Oncol Biol Phys2011https://conductscience.org/library/papers/20732762PubMed
331666247Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study.Clin Cancer Res2020https://conductscience.org/library/papers/31666247PubMed
412234397Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis.Neurosurgery2002https://conductscience.org/library/papers/12234397PubMed
533105661A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma.Cancers (Basel)2020https://conductscience.org/library/papers/33105661PubMed
634594572Redo craniotomy or bevacizumab for symptomatic steroid-refractory true or pseudoprogression following IMRT for glioblastoma.Neurooncol Pract2021https://conductscience.org/library/papers/34594572PubMed
734899760Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma.Front Immunol2021https://conductscience.org/library/papers/34899760PubMed
830627060Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas.Contrast Media Mol Imaging2018https://conductscience.org/library/papers/30627060PubMed
918452856Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.Lancet Oncol2008https://conductscience.org/library/papers/18452856PubMed
1029590461Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.Neuro Oncol2018https://conductscience.org/library/papers/29590461PubMed
1134297308Emerging Technologies for Non-invasive Monitoring of Treatment Response to Immunotherapy for Brain Tumors.Neuromolecular Med2022https://conductscience.org/library/papers/34297308PubMed
1216517093Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy.Int J Radiat Oncol Biol Phys2006https://conductscience.org/library/papers/16517093PubMed
1319221865Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression.J Neurooncol2009https://conductscience.org/library/papers/19221865PubMed
1435821676Standard clinical approaches and emerging modalities for glioblastoma imaging.Neurooncol Adv2022https://conductscience.org/library/papers/35821676PubMed
1526545842Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.Lancet Oncol2015https://conductscience.org/library/papers/26545842PubMed
1629390403Tumor recurrence versus treatment effects in glioma: A comparative study of three dimensional pseudo-continuous arterial spin labeling and dynamic susceptibility contrast imaging.Medicine (Baltimore)2017https://conductscience.org/library/papers/29390403PubMed
1733085022The histological representativeness of glioblastoma tissue samples.Acta Neurochir (Wien)2021https://conductscience.org/library/papers/33085022PubMed
1826382848Proliferation Index Predicts Survival after Second Craniotomy within 6 Months of Adjuvant Radiotherapy for High-grade Glioma.Clin Oncol (R Coll Radiol)2016https://conductscience.org/library/papers/26382848PubMed
1931844891Toward a standard pathological and molecular characterization of recurrent glioma in adults: a Response Assessment in Neuro-Oncology effort.Neuro Oncol2020https://conductscience.org/library/papers/31844891PubMed
2019834699Distinction between glioma progression and post-radiation change by combined physiologic MR imaging.Neuroradiology2010https://conductscience.org/library/papers/19834699PubMed

See all 79 referencesDownload CSV of references

Cited by46

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 48 citations.

PMIDTitleJournalYearIn PapersSource
42974199Differentiating true progression from pseudoprogression in glioblastomas: Dynamic contrast-enhanced MRI habitat analysis with parsimonious pharmacokinetic model.Neurooncol Adv2026https://conductscience.org/library/papers/42974199PubMed
42942170Threshold-Independent Amide Proton Transfer-Weighted MRI in Post-Treatment Gliomas: A Systematic Review and Meta-Analysis of Effect Size and Diagnostic Accuracy.Life (Basel)2026https://conductscience.org/library/papers/42942170PubMed
42907136Cell-based therapies for malignant glioma.Stem Cells Transl Med2026https://conductscience.org/library/papers/42907136PubMed
42902051Sonolucent cranial windows for bedside ultrasound identification of MRI-concordant glioblastoma recurrence during outpatient surveillance: an imaging correlation pilot study.Acta Neurochir (Wien)2026https://conductscience.org/library/papers/42902051PubMed
42896233
Quantitative, longitudinal measurements of response to immunotherapy for glioblastoma using multiparametric MRI in a long-term survivor treated with autologous tumor lysate-loaded dendritic cell vaccine: an illustrative case.
J Neurosurg Case Lessons2026https://conductscience.org/library/papers/42896233PubMed
42829361Early experience with cerebrospinal fluid cell-free DNA molecular profiling in a neuro-oncology practice.J Neurooncol2026https://conductscience.org/library/papers/42829361PubMed
42682614Calibrated and explainable multiparametric MRI radiomics for differentiating tumor positive disease from treatment-related changes in glioblastoma.Front Oncol2026https://conductscience.org/library/papers/42682614PubMed
42396282Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.medRxiv2026https://conductscience.org/library/papers/42396282PubMed
42271271Microstructural MRI combined with metabolic MRI to evaluate the progression-free survival of patients with glioblastoma at the early follow-up after tumor treating fields: a pilot study.BMC Med Imaging2026https://conductscience.org/library/papers/42271271PubMed
42189415Peripheral hematological landscapes as biomarkers for detecting postoperative progression in glioblastoma multiforme: a multivariable risk scoring approach.J Neurooncol2026https://conductscience.org/library/papers/42189415PubMed
42078261Neuro-Oncology Biotech Industry Progress Report 2025.Cureus2026https://conductscience.org/library/papers/42078261PubMed
42016861Microfluidic approaches for liquid biopsy in glioblastoma: Insights into diagnostic and follow-up strategies.Bioeng Transl Med2026https://conductscience.org/library/papers/42016861PubMed
41841145Artificial intelligence-based volumetric measurements for longitudinal clinical assessment of treatment response in high-grade gliomas: Validation across institutional and public datasets.Neurooncol Adv2026https://conductscience.org/library/papers/41841145PubMed
41808979Intraosseous Pseudoprogression vs. Progression and Recurrence of Clival Chordoma after Proton Radiation Therapy: Case Series.J Neurol Surg B Skull Base2026https://conductscience.org/library/papers/41808979PubMed
41803972Radiomics in glioblastoma recurrence: advances in prediction, localization, and differentiation from treatment-related effects.J Transl Med2026https://conductscience.org/library/papers/41803972PubMed
41733867Repeat resection for recurrent glioblastoma - does timing matter?J Neurooncol2026https://conductscience.org/library/papers/41733867PubMed
41677672Decoding Glioblastoma Through Liquid Biopsy: Molecular Insights and Clinical Prospects.Cells2026https://conductscience.org/library/papers/41677672PubMed
41597259Advancing Bioconjugated Quantum Dots with Click Chemistry and Artificial Intelligence to Image and Treat Glioblastoma.Cells2026https://conductscience.org/library/papers/41597259PubMed
41514549Timepoint-Specific Benchmarking of Deep Learning Models for Glioblastoma Follow-Up MRI.Cancers (Basel)2025https://conductscience.org/library/papers/41514549PubMed
41289012Daily locomotor activity declines with tumor growth and disease progression in glioblastoma.JCI Insight2026https://conductscience.org/library/papers/41289012PubMed

See all 46 cited byDownload CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ANXA5308PubTator's text mininghttps://conductscience.org/library/genes/308NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
IDH13417PubTator's text mininghttps://conductscience.org/library/genes/3417NCBI Gene
MGMT4255PubTator's text mininghttps://conductscience.org/library/genes/4255NCBI Gene
TP537157PubTator's text mininghttps://conductscience.org/library/genes/7157NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36790010

GET https://conductscience.org/api/papers/v1/36790010/references?page=2